Insulin Detemir

證據等級: L5

預測適應症: 10 個

Insulin Detemir: From Diabetes Management to Type 1 Diabetes Mellitus

One-Sentence Summary

Insulin detemir (Levemir®) is a long-acting basal insulin analogue developed by Novo Nordisk that is globally established for diabetes management, but is currently not registered in Singapore. The TxGNN model predicts it may be effective for Type 1 Diabetes Mellitus (T1DM), with 50+ clinical trials and 19 publications currently supporting this direction — confirming a mechanistically direct and clinically well-validated therapeutic use rather than a speculative repurposing hypothesis. The overall evidence package is rated L1, making this one of the strongest possible candidate profiles in a TxGNN evaluation.

Quick Overview

Item	Content
Original Indication	No Singapore registration (globally used for diabetes mellitus)
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.77%
Evidence Level	L1
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Insulin detemir is a soluble, long-acting human insulin analogue structurally modified by acylation with a C14 fatty acid (myristic acid) at the B29 lysine residue. Following subcutaneous injection, insulin detemir reversibly binds to albumin at the injection site and in the bloodstream, dramatically slowing systemic absorption and producing a flat, prolonged pharmacodynamic profile lasting up to 24 hours. This mechanism results in significantly lower intrapatient variability compared to NPH (Neutral Protamine Hagedorn) insulin, meaning more predictable glucose control and a reduced risk of nocturnal hypoglycaemia.

Type 1 Diabetes Mellitus arises from autoimmune destruction of pancreatic β-cells, resulting in absolute endogenous insulin deficiency. Insulin detemir addresses this deficiency through a direct causal mechanism: it binds the insulin receptor (IR) → activates IRS phosphorylation → triggers the PI3K/Akt pathway → promotes GLUT4 translocation to cell membranes for glucose uptake in muscle and adipose tissue, while simultaneously suppressing hepatic glucose output (HGO), lipolysis, and ketogenesis. This is not an extrapolation across disease areas — it is the foundational mechanism of insulin replacement therapy.

The TxGNN model prediction therefore reflects an established clinical reality. Insulin detemir holds regulatory approval in the EU (EMA, 2004), the US (FDA, 2005), and Japan (PMDA), specifically for use as basal insulin in a basal-bolus regimen for T1DM. Multiple completed Phase 3 RCTs demonstrate that it reduces HbA1c comparably to, with a superior hypoglycaemia and body weight profile versus, NPH insulin. The prediction score of 99.77% is consistent with this level of mechanistic directness and clinical validation. The primary gap identified in this evaluation is the absence of Singapore HSA registration and formal local safety documentation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00184665	Phase 3	Completed	501	Multinational 2-year RCT (Africa, Asia, Europe, Oceania, South America) directly comparing Insulin Detemir vs NPH insulin in T1DM; evaluated HbA1c reduction, hypoglycaemia frequency, body weight, and insulin antibody formation — the core long-term pivotal evidence
NCT00474045	Phase 3	Completed	470	Multinational RCT comparing Insulin Detemir + Insulin Aspart vs NPH + Insulin Aspart in pregnant women with T1DM; directly evaluated blood glucose control and maternal-fetal safety in this high-risk population
NCT01831765	Phase 3	Completed	1,290	52-week European/US trial comparing faster-acting insulin aspart (FIAsp) vs Insulin Aspart, both in combination with Insulin Detemir as basal, in adult T1DM; confirms Detemir's established role as standard-of-care basal comparator
NCT01697657	Phase 3	Completed	131	Cross-over RCT (Africa, Europe, Oceania) specifically investigating whether Insulin Detemir vs NPH insulin reduces hypoglycaemia frequency while maintaining equivalent glycaemic control in well-controlled T1DM on basal-bolus regimen
NCT01835431	Phase 3	Completed	362	International trial (Asia, Europe, Americas) comparing IDegAsp once daily vs Insulin Detemir once or twice daily as basal in children and adolescents with T1DM; extends Detemir evidence to paediatric population
NCT00487240	Phase 3	Completed	387	Treat-to-target RCT comparing Insulin Lispro Protamine Suspension (ILPS) vs Insulin Detemir as basal in T1DM basal-bolus therapy; sequential gatekeeper statistical approach for efficacy and safety endpoints
NCT01454284	Phase 3	Completed	1,114	52-week double-blind RCT comparing LY2605541 vs Insulin Glargine in T1DM on Insulin Lispro; Insulin Detemir used as pre-study basal insulin, affirming its clinical benchmark status in the T1DM basal insulin landscape
NCT00841087	Phase 2	Completed	65	Japanese exploratory RCT assessing safety (emphasis on hypoglycaemia) of switching from long-acting analogues including Insulin Detemir to Insulin Degludec (NN1250) in T1DM on basal-bolus regimen
NCT01542450	Phase 1	Completed	23	Japanese single-centre crossover PK/PD study comparing Insulin Detemir vs NPH insulin in Japanese T1DM subjects; provides pharmacokinetic evidence in Asian population specifically
NCT01497574	Phase 1	Completed	32	Crossover PK trial comparing within-subject variability of Insulin Detemir vs Insulin Glargine pharmacokinetic profiles in children and adolescents with T1DM

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36623517	2023	Comparative RCT	The Lancet Diabetes & Endocrinology	EXPECT trial: non-inferiority RCT comparing Insulin Degludec vs Insulin Detemir (both combined with Insulin Aspart) in pregnant women with T1DM; directly validates Detemir's efficacy and safety profile in this high-risk subgroup and establishes it as the active comparator for next-generation basal insulins
36763996	2022	Systematic Review / Meta-Analysis	Clinical Therapeutics	Meta-analysis comparing Insulin Degludec vs Glargine and Detemir in T1D and T2D; quantified comparative HbA1c reduction, hypoglycaemia rates, and tolerability — positions Detemir within the current basal insulin hierarchy
29477399	2018	Systematic Review + Network Meta-Analysis	Value in Health	Network meta-analysis assessing relative efficacy and safety of all basal insulin regimens in adult T1DM; provides head-to-head comparative positioning of Insulin Detemir versus all available basal insulin options
37290466	2023	Clinical Practice Guideline	The Lancet Diabetes & Endocrinology	Updated management guidelines for T1DM in pregnancy, covering glycaemic targets, basal insulin selection (including Detemir), and integration of continuous glucose monitoring and insulin pumps
21878861	2011	Systematic Review + Meta-Analysis	Polskie Archiwum Medycyny Wewnętrznej	Systematic review of Insulin Detemir vs NPH insulin in T1DM; assessed glycaemic control improvements, hypoglycaemia reduction, and body weight effects — summarised both supportive and conflicting findings
23110609	2012	Review	Drugs	Comprehensive review of Insulin Detemir pharmacology, PK/PD properties, and clinical trial data across T1DM and T2DM; includes glucose-clamp evidence for reduced within-patient variability vs NPH insulin and Glargine
20539842	2010	Review	Vascular Health and Risk Management	Clinical review of Insulin Detemir for T1DM and T2DM; compared HbA1c outcomes and hypoglycaemia rates versus NPH insulin and discussed the weight-neutral advantage of Detemir
17326333	2006	Review	Vascular Health and Risk Management	Mechanistic and clinical review of Insulin Detemir at early post-approval stage; explained albumin-binding mechanism and clinical benefits in reducing nocturnal hypoglycaemia in T1DM and T2DM
15516157	2004	Review	Drugs	Seminal review of Insulin Detemir at time of regulatory submission; described the C14 fatty acid modification, albumin-binding mechanism, and early Phase 2/3 clinical efficacy data
36896906	2024	Review of Clinical Trials + Real-World Evidence	Current Diabetes Reviews	Two-decade review of Insulin Glargine vs Detemir across clinical trials and real-world studies in T1DM; contextualises Detemir's comparative effectiveness and its position as a validated active comparator in T1DM basal insulin studies

Singapore Market Information

Insulin detemir (Levemir®) is currently not registered with the Health Sciences Authority (HSA) in Singapore. No product licences have been identified.

Important context: Insulin detemir holds regulatory approval in the EU (EMA approval 2004), the US (FDA approval 2005), Japan (PMDA), and numerous other jurisdictions for use in both Type 1 and Type 2 Diabetes Mellitus. The absence of Singapore registration likely reflects commercial decisions by Novo Nordisk rather than safety or efficacy concerns. Clinicians and evaluators should also note that Novo Nordisk announced the discontinuation of Levemir® in certain markets (including the US, effective December 2023) as part of a portfolio strategy favouring next-generation basal insulins (Insulin Degludec/Tresiba®). The current global availability status should be confirmed with the manufacturer before proceeding with a Singapore registration application.

Safety Considerations

Please refer to the package insert for safety information.

Safety data including key warnings, contraindications, and drug-drug interactions were not available in the current Evidence Pack. The European Medicines Agency SmPC (Levemir®) and/or the original US FDA prescribing information should be reviewed in full prior to clinical use. Key areas to assess include: hypoglycaemia (most common adverse effect), hypokalaemia risk, injection site lipodystrophy with long-term use, dose adjustments in renal or hepatic impairment, use in pregnancy and lactation, and interactions with other antidiabetic agents, beta-blockers, and drugs affecting glucose metabolism.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Insulin detemir carries the strongest possible evidence base — Level 1 (multiple completed Phase 3 RCTs with thousands of T1DM patients) — and a mechanistically direct and causally validated relationship with Type 1 Diabetes Mellitus. The TxGNN prediction confirms an already-approved global indication. The primary barriers to use in Singapore are the absence of HSA registration and a strategic uncertainty regarding the drug's continued commercial availability, given Novo Nordisk's portfolio withdrawal in some markets.

To proceed, the following is needed:

Confirm global market status: Verify whether Novo Nordisk intends to maintain Levemir® supply in the Asia-Pacific region or whether Singapore will be affected by the withdrawal seen in the US market
Obtain complete safety documentation: Download and review the current EMA SmPC or PMDA package insert for key warnings, contraindications, special population guidance, and drug interactions
Assess therapeutic alternatives: Evaluate whether alternative basal insulins already registered with HSA Singapore (e.g., Insulin Glargine or Insulin Degludec) adequately meet clinical needs before pursuing a new NDA for Detemir
If registration is pursued: Prepare an HSA New Drug Application leveraging existing Phase 3 trial data from the EU/US regulatory submissions; PK bridging data in Asian populations may be required (the NCT01542450 Japanese PK study provides partial support)
Pharmacovigilance plan: Establish a hypoglycaemia monitoring and injection technique education programme specific to the Singapore T1DM patient population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.